Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tatsuo Tsukamoto is active.

Publication


Featured researches published by Tatsuo Tsukamoto.


Journal of Obstetrics and Gynaecology Research | 2015

Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks' gestation.

Baku Nakakita; Haruta Mogami; Eiji Kondoh; Tatsuo Tsukamoto; Motoko Yanagita; Ikuo Konishi

Soluble fms‐like tyrosine kinase‐1 (sFlt1), a circulating vascular endothelial growth factor receptor 1 antagonist, is associated with the pathogenesis of pre‐eclampsia. Extracorporeal removal of sFlt1 (sFlt1 apheresis) is emerging as a treatment for pre‐eclampsia. We performed sFlt1 apheresis for a patient with very early onset pre‐eclampsia, beginning at 15 weeks’ gestation. She underwent sFlt1 apheresis 13 times from 19 to 23 weeks’ gestation. The series of treatments lowered circulating sFlt1, stabilized blood pressure, reduced urinary protein, and preserved renal function, which contributed to a successful prolongation of pregnancy for 4 weeks and a live birth at 23+3 weeks’ gestation. Further studies are necessary for clinical application of sFlt1 apheresis as sFlt1 might have a protective function for the placenta and fetus in pre‐eclampsia.


Clinical Journal of The American Society of Nephrology | 2017

Maternal Smoking during Pregnancy, Household Smoking after the Child’s Birth, and Childhood Proteinuria at Age 3 Years

Maki Shinzawa; Shiro Tanaka; Hironobu Tokumasu; Daisuke Takada; Tatsuo Tsukamoto; Motoko Yanagita; Koji Kawakami

BACKGROUND AND OBJECTIVES Smoking is a well known risk factor of proteinuria in adults; however, clinical studies in children are limited. The purpose of this study is to clarify the associations of maternal smoking during pregnancy and household smoking after the childs birth with the risk of proteinuria at age 3 years old. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We performed a population-based retrospective cohort study on 44,595 children using data on prenatal health checkups, home visit neonatal health checkups, and health checkups at 4, 9, and 18 months and 3 years of age in Kobe City, Japan. Maternal smoking status (nonsmoker, past smoker, or current smoker) was collected with standardized questionnaires. The outcome of interest was the presence of proteinuria at 3 years of age defined as urinary protein ≥1+. To evaluate the association between child proteinuria and smoking status, we performed multivariate logistic regression model analyses adjusted for confounding factors. RESULTS The prevalence rates of children in the maternal smoking groups (none, past, and current) were 78.9%, 4.4%, and 16.7%, respectively. The frequencies of child proteinuria defined as ≥1+ urinary protein were 1.7% in the current smoking group, 1.6% in the past smoking group, and 1.3% in the nonsmoking group. Maternal smoking during pregnancy was associated with child proteinuria (odds ratio, 1.24; 95% confidence interval, 1.00 to 1.52; P=0.05) in the multiple logistic regression model, although nonmaternal family smoking during pregnancy was not significantly associated with child proteinuria (odds ratio, 0.97; 95% confidence interval, 0.79 to 1.19; P=0.77). We also found a similar association with household smoking after the childs birth (odds ratio, 1.23; 95% confidence interval, 0.99 to 1.54; P=0.06), although this observation was not significant. CONCLUSIONS Maternal smoking during pregnancy was one of the risk factors of childhood proteinuria. We also found a similar association with household smoking after the childs birth, although this observation was not significant.


American Journal of Nephrology | 2016

Annual Iron Loss Associated with Hemodialysis

Tatsuo Tsukamoto; Takayuki Matsubara; Yuka Akashi; Morihiro Kondo; Motoko Yanagita

Background: In order to keep up the optimal iron status in chronic hemodialysis patients, it is important to know how much iron is lost due to hemodialysis. Residual blood associated with the hemodialysis procedure together with blood sampling inevitably causes the loss of iron in chronic hemodialysis patients. Recent advances in hemodialysis techniques might have reduced this complication. In this cross-sectional study, we directly measured total iron loss by hemodialysis. Methods: Two hundred thirty-nine patients who received chronic hemodialysis at Otowa Memorial Hospital were enrolled; 65.7% of patients were men, and mean age was 67 ± 6.4 years (mean ± SD) and 43.2% were diabetic. Residual blood in blood tubing set and dialyzer after rinse back with saline was collected and homogenized. The iron content including free, protein-bound and heme iron was measured using an atomic absorption spectrometry. Results: The mean iron content in residual blood was 1,247.3 ± 796.2 µg (mean ± SD) and the median was 1,002 µg (95% CI 377.6-3,461.6 µg), indicating 160.8 mg (95% CI 58.9-540.0 mg) iron loss annually when hemodialysis was performed 156 times a year. Fifty milliliter whole blood for monthly blood test and another 2 ml of whole blood lost by paracentesis at every dialysis session contains 228.6 and 118.9 mg iron at 11 g/dl hemoglobin, respectively. Therefore, an annual total iron loss due to hemodialysis comes to 508.3 mg (95% CI 406.4-887.5 mg). Conclusions: Five hundred milligram of annual iron supplementation might be sufficient to maintain iron status in hemodialysis patients, which is less than the dose recommended as 1,000-2,000 mg a year. Further study will be required to verify this iron supplementation dosage with recent hemodialysis procedure.


Nephrology | 2015

Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy

Kyoko Tobino; Eri Muso; Yukako Iwasaki; Satomi Yonemoto; Kenji Kasuno; Tatsuo Tsukamoto; Hajime Nakamura; Yasuhiko Tomino

The role of urinary (U‐) thioredoxin (Trx), a class of small redox proteins, in physiological and pathological conditions, in addition to its gender specificity, has been insufficiently determined in chronic kidney disease (CKD) patients, especially in diabetes mellitus (DM) nephropathy.


Journal of intensive care | 2018

The Japanese Clinical Practice Guideline for acute kidney injury 2016

Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada

Acute kidney injury (AKI) is a syndrome which has a broad range of etiologic factors depending on different clinical settings. Because AKI has significant impacts on prognosis in any clinical settings, early detection and intervention are necessary to improve the outcomes of AKI patients. This clinical guideline for AKI was developed by a multidisciplinary approach with nephrology, intensive care medicine, blood purification, and pediatrics. Of note, clinical practice for AKI management which was widely performed in Japan was also evaluated with comprehensive literature search.


Clinical and Experimental Nephrology | 2018

Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study

Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Kosaku Nitta; Tatsuo Tsukamoto; Shunya Uchida; Asami Takeda; Toshinobu Sato; Takashi Wada; Hiroki Hayashi; Yasuhiro Akai; Megumu Fukunaga; Kazuhiko Tsuruya; Kosuke Masutani; Tsuneo Konta; Tatsuya Shoji; Takeyuki Hiramatsu; Shunsuke Goto; Hirofumi Tamai; Saori Nishio; Arimasa Shirasaki; Kojiro Nagai; Kunihiro Yamagata; Hajime Hasegawa; Hidemo Yasuda; Shizunori Ichida; Tomohiko Naruse; Kei Fukami

BackgroundThe lack of high-quality clinical evidences hindered broad consensus on optimal therapies for primary nephrotic syndromes. The aim of the present study was to compare prevalence of immunosuppressive drug use in patients with primary nephrotic syndrome across 6 regions in Japan.MethodsBetween 2009 and 2010, 380 patients with primary nephrotic syndrome in 56 hospitals were enrolled in a prospective cohort study [Japan Nephrotic Syndrome Cohort Study (JNSCS)], including 141, 151, and 38 adult patients with minimal change disease (MCD), membranous nephropathy (MN), and focal segmental glomerulosclerosis (FSGS), respectively. Their clinical characteristics were compared with those of patients registered in a large nationwide registry of kidney biopsies [Japan Renal Biopsy Registry (J-RBR)]. The regional prevalence of use of each immunosuppressive drug was assessed among adult MCD, MN, and FSGS patients who underwent immunosuppressive therapy in the JNSCS (n = 139, 127, and 34, respectively). Predictors of its use were identified using multivariable-adjusted logistic regression models.ResultsThe clinical characteristics of JNSCS patients were comparable to those of J-RBR patients, suggesting that the JNSCS included the representatives in the J-RBR. The secondary major immunosuppressive drugs were intravenous methylprednisolone [n = 33 (24.6%), 24 (19.7%), and 9 (28.1%) in MCD, MN, and FSGS, respectively] and cyclosporine [n = 25 (18.7%), 62 (50.8%), and 16 (50.0%), respectively]. The region was identified as a significant predictor of use of intravenous methylprednisolone in MCD and MN patients.ConclusionUse of intravenous methylprednisolone for MCD and MN differed geographically in Japan. Its efficacy should be further evaluated in a well-designed trial.


Clinical and Experimental Nephrology | 2018

The Japanese clinical practice guideline for acute kidney injury 2016

Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada

Acute kidney injury (AKI) is a syndrome which has a broad range of etiologic factors depending on different clinical settings. Because AKI has significant impacts on prognosis in any clinical settings, early detection and intervention is necessary to improve the outcomes of AKI patients. This clinical guideline for AKI was developed by a multidisciplinary approach with nephrology, intensive care medicine, blood purification, and pediatrics. Of note, clinical practice for AKI management which was widely performed in Japan was also evaluated with comprehensive literature search.


Clinical Epidemiology | 2018

Acetaminophen administration and the risk of acute kidney injury: a self-controlled case series study

Shusuke Hiragi; Hiroyuki Yamada; Tatsuo Tsukamoto; Kazuki Yoshida; Naoya Kondo; Takeshi Matsubara; Motoko Yanagita; Hiroshi Tamura; Tomohiro Kuroda

Background Acetaminophen (APAP) is frequently used for analgesia and is considered safer than nonsteroidal anti-inflammatory drugs (NSAIDs) for the kidneys. However, there is little epidemiological evidence of the association between APAP and acute kidney injury (AKI). Objectives To examine the association between APAP and AKI using the self-controlled case series (SCCS) method, which is a novel strategy to control between-person confounders by comparing the risk and reference periods in each patient. Methods We performed SCCS in 1,871 patients (39.9% female) who were administered APAP and subsequently developed AKI, by reviewing electronically stored hospital information system data from May 2011 to July 2016. We used conditional Poisson regression to compare each patient’s risk and reference period. As a time-varying confounder, we adjusted the status of liver and kidney functions, systemic inflammation, and exposure to NSAIDs. Results We identified 5,650 AKI events during the 260,549 person-day observation period. The unadjusted incidences during the reference and exposure periods were 2.01/100 and 3.12/100 person-days, respectively. The incidence rate ratio adjusted with SCCS was 1.03 (95% confidence interval [CI]: 0.95–1.12). When we restricted endpoints as stage 2 AKI- and stage 3 AKI-level creatinine elevations, the incidence rate ratios were 1.20 (95% CI 0.91–1.58) and 1.20 (95% CI 0.62–2.31), respectively, neither of which was statistically significant. Conclusion Our findings added epidemiological information for the relationship between APAP administration and AKI development. The results indicated scarce association between APAP and AKI, presumably supporting the general physicians’ impression that APAP is safer for kidney.


Circulation | 2018

Outcome From a Randomized Controlled Clinical Trial ― Improvement of Peripheral Arterial Disease by Granulocyte Colony-Stimulating Factor-Mobilized Autologous Peripheral-Blood-Mononuclear Cell Transplantation (IMPACT) ―

Takashi Horie; Seiji Yamazaki; Sayaka Hanada; Shuzo Kobayashi; Tatsuo Tsukamoto; Tetsuya Haruna; Katsuhiko Sakaguchi; Ken Sakai; Hideaki Obara; Kiyofumi Morishita; Kenichi Saigo; Yoshiaki Shintani; Kohmei Kubo; Junichi Hoshino; Teiji Oda; Eiji Kaneko; Masaharu Nishikido; Tetsuya Ioji; Hideaki Kaneda; Masanori Fukushima

BACKGROUND The clinical usefulness of peripheral blood (PB) mononuclear cell (MNC) transplantation in patients with peripheral arterial disease (PAD), especially in those with mild-to-moderate severity, has not been fully clarified.Methods and Results:A randomized clinical trial was conducted to evaluate the efficacy and safety of granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation in patients with PAD (Fontaine stage II-IV and Rutherford category 1-5) caused by arteriosclerosis obliterans or Buergers disease. The primary endpoint was progression-free survival (PFS). In total, 107 subjects were enrolled. At baseline, Fontaine stage was II/III in 82 patients and IV in 21, and 54 patients were on hemodialysis. A total of 50 patients had intramuscular transplantation of PBMNC combined with standard of care (SOC) (cell therapy group), and 53 received SOC only (control group). PFS tended to be improved in the cell therapy group than in the control group (P=0.07). PFS in Fontaine stage II/III subgroup was significantly better in the cell therapy group than in the control group. Cell therapy-related adverse events were transient and not serious. CONCLUSIONS In this first randomized, large-scale clinical trial of G-CSF-mobilized PBMNC transplantation, the cell therapy was tolerated by a variety of PAD patients. The PBMNC therapy was significantly effective for inhibiting disease progression in mild-to-moderate PAD.


CEN Case Reports | 2018

Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report

Eiichiro Uchino; Daisuke Takada; Haruta Mogami; Takeshi Matsubara; Tatsuo Tsukamoto; Motoko Yanagita

Pregnancy and membranous nephropathy (MN) can occur concurrently with nephrotic syndrome. However, the pathophysiology of MN associated with pregnancy remains unclear, including the involvement of anti-M-type phospholipase A2 receptor (PLA2R) antibody, the major antigen of idiopathic MN (iMN). A treatment for the condition is also not established. We present the case of a 43-year-old pregnant female with incidental proteinuria and hypoalbuminemia. We made a diagnosis of nephrotic syndrome at 11 week gestation. Renal biopsy revealed iMN using predominant granular staining of IgG4 along the glomerular basement membrane. No secondary cause was identified. Oral glucocorticoid therapy was started from 17 week gestation and induced complete remission at 28 week gestation. A healthy infant was born at 38 week gestation. Glucocorticoid therapy was stopped postpartum without MN relapse. Anti-PLA2R antibody was later found to be positive using serum reserved from before treatment. In conclusion, we presented the case of a pregnant woman with iMN and anti-PLA2R antibodies, whose nephrotic syndrome was successfully controlled with oral glucocorticoids to reach complete remission, even after tapering off the medication. Pregnancy per se might be associated with iMN onset.

Collaboration


Dive into the Tatsuo Tsukamoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yugo Shibagaki

St. Marianna University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yukio Yuzawa

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daisuke Koya

Kanazawa Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge